Genetics and pathophysiology of systemic sclerosis

被引:2
|
作者
Allanore, Yannick [1 ,2 ]
Boileau, Catherine [3 ,4 ,5 ]
机构
[1] Univ Paris 05, Hop Cochin, INSERM, U1016, F-75679 Paris 14, France
[2] APHP, F-75679 Paris 14, France
[3] Hop Ambroise Pare, Lab Biochim Hormonale & Genet, Boulogne, France
[4] Univ Versailles St Quentin Yvelines, Versailles, France
[5] Hop Bichat Claude Bernard, AP HP, INSERM, U698, F-75877 Paris, France
来源
关键词
SCLERODERMA SYSTEMIC; GENETICS; POLYMORPHISM; GENETIC; AUTOIMMUNITY; FUNCTIONAL POLYMORPHISM; RISK-FACTOR; ASSOCIATION; SUSCEPTIBILITY; IRF5; SCLERODERMA; EXPRESSION; REGION; CELLS; STAT4;
D O I
10.1016/S0001-4079(19)32136-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic sclerosis (SSc) is a connective tissue disease characterized by early generalized microangiopathy, immunological disorders, and massive overproduction and accumulation of collagen and other matrix components in connective tissue. Although rare, SSc may be considered as is the most severe connective tissue disorder and a major medical challenge. Molecular biology has led to notable progress into genetic predisposing factors and the complex pathogenesis of SSc. Large scale studies have revealed robust genetic associations with several factors involved in autoimmunity, while associations with vascular and fibrotic factors are weaker or have not been independently replicated. The major histocompatibility complex genes are the most important genomic region in many autoimmune disorders, including SSc. Candidate-gene and genome-wide studies point to a key role of genes encoding proteins involved in innate and adaptive immunity. Interactions between genes and environmental factors need to be further investigated. Improvements in diagnostic and prognostic tools are anticipated in the near future, together with more specific immune therapy for these patients, for whom specific treatment is not currently available.
引用
收藏
页码:55 / 65
页数:11
相关论文
共 50 条
  • [41] Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment
    Richardson, Carrie
    Plaas, Anna
    Varga, John
    CURRENT RHEUMATOLOGY REPORTS, 2020, 22 (10)
  • [42] B cells in systemic sclerosis: from pathophysiology to treatment
    Melissaropoulos, Konstantinos
    Daoussis, Dimitrios
    CLINICAL RHEUMATOLOGY, 2021, 40 (07) : 2621 - 2631
  • [43] Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches
    Benfaremo, Devis
    Svegliati, Silvia
    Paolini, Chiara
    Agarbati, Silvia
    Moroncini, Gianluca
    BIOMEDICINES, 2022, 10 (01)
  • [44] Systemic sclerosis pathogenesis: contribution of recent advances in genetics
    Orvain, Cindy
    Assassi, Servin
    Avouac, Jerome
    Allanore, Yannick
    CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (06) : 505 - 514
  • [45] PATHOPHYSIOLOGY AND GENETICS
    Enerback, Charlotta
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 7 - 7
  • [46] Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma)
    Sallam, H
    McNearney, TA
    Chen, JDZ
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (06) : 691 - 712
  • [47] Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis
    Sunderkoetter, C.
    Riemekasten, G.
    RHEUMATOLOGY, 2006, 45 : 33 - 35
  • [48] Pathophysiology and recent findings of primary biliary cirrhosis complicated by systemic sclerosis
    Ohira, Hiromasa
    Watanabe, Hiroshi
    HEPATOLOGY RESEARCH, 2014, 44 (04) : 377 - 383
  • [49] Genetics and the pathophysiology of obesity
    Clément, K
    Ferré, P
    PEDIATRIC RESEARCH, 2003, 53 (05) : 721 - 725
  • [50] Pathophysiology and genetics of deafness
    Loundon, N.
    ARCHIVES DE PEDIATRIE, 2006, 13 (06): : 772 - 774